• 1.

    Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:22952306. doi: 10.1056/NEJMoa1811744

  • 2.

    Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:14361446. doi: 10.1056/NEJMoa2024816

  • 3.

    Bakris GL, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383:22192229. doi: 10.1056/NEJMoa2025845

  • 4.

    Pitt B, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021; 385:22522263. doi: 10.1056/NEJMoa2110956

  • 5.

    Provenzano M, et al. Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: A randomized crossover clinical trial. J Am Soc Nephrol 2022; 33:15691580. doi: 10.1681/ASN.2022020207

    • PubMed
    • Search Google Scholar
    • Export Citation

Adding Mineralocorticoid Receptor Antagonists to SGLT2 Inhibitors: Should We Push the Envelope?

Micah Schub Micah Schub, MD, is a nephrology fellow at Duke University, Durham, NC. Matthew A. Sparks, MD, FASN, is an Associate Professor of Medicine; Program Director of Nephrology Fellowship; and Lead, Society for Early Education Scholars (SEEDS) program, Department of Medicine, Duke University, and Staff Physician, Durham VA Health Care System, Durham, NC.

Search for other papers by Micah Schub in
Current site
Google Scholar
PubMed
Close
and
Matthew A. Sparks Micah Schub, MD, is a nephrology fellow at Duke University, Durham, NC. Matthew A. Sparks, MD, FASN, is an Associate Professor of Medicine; Program Director of Nephrology Fellowship; and Lead, Society for Early Education Scholars (SEEDS) program, Department of Medicine, Duke University, and Staff Physician, Durham VA Health Care System, Durham, NC.

Search for other papers by Matthew A. Sparks in
Current site
Google Scholar
PubMed
Close
Restricted access
Save